Allegedly Submitted False Medicare Claims for Drug Provided to Dialysis Patients
Washington, DC–(ENEWSPF)–May 21, 2013. U.S. Renal Care, headquartered in Plano, Texas, has agreed to pay $7.3 million to resolve allegations that Dialysis Corporation of America (DCA) violated the False Claims Act by submitting false claims to the Medicare program for more Epogen than was actually administered to dialysis patients at DCA facilities, the Justice Department announced today. U.S. Renal Care, which acquired DCA in…
